中国基层医药
中國基層醫藥
중국기층의약
CHINESE JOURNAL OF PRIMARY MEDICINE AND PHARMACY
2013年
18期
2747-2749
,共3页
糖尿病神经病变%α-硫辛酸%单唾液酸四己糖神经节苷脂
糖尿病神經病變%α-硫辛痠%單唾液痠四己糖神經節苷脂
당뇨병신경병변%α-류신산%단타액산사기당신경절감지
Diabetic neuropathies%Alpha-Lipoic acid%Monosialotetrahexosylganglioside
目的 探讨α-硫辛酸(ALA)联合单唾液酸四己糖神经节苷脂(GM1)治疗糖尿病周围神经病变(DPN)的治疗效果.方法 将98例2型糖尿病(T2DM)伴有DPN的患者遵照知情同意原则采用随机数字表法分为对照组和治疗组,各49例.对照组给予ALA 600 mg静脉滴注1次/d,治疗组在对照组的基础上加用GMI 60 mg静脉滴注1次/d,共3周.观察治疗前后神经系统症状和体征变化,测量神经传导速度(NCV)和空腹血糖,检查膝腱和跟腱反射、血尿常规和肝肾功能等.结果 治疗组总有效率为91.84％,明显高于对照组的67.35％(χ2=52.01,P＜0.05).治疗后治疗组运动神经传导速度(MNCV)、感觉神经传导速度(SNCV)增加幅度均显著高于对照组(t=1.987、1.972、1.972、1.972,均P＜0.05).结论 ALA联合GM1治疗糖尿病周围神经病变安全、疗效明显.
目的 探討α-硫辛痠(ALA)聯閤單唾液痠四己糖神經節苷脂(GM1)治療糖尿病週圍神經病變(DPN)的治療效果.方法 將98例2型糖尿病(T2DM)伴有DPN的患者遵照知情同意原則採用隨機數字錶法分為對照組和治療組,各49例.對照組給予ALA 600 mg靜脈滴註1次/d,治療組在對照組的基礎上加用GMI 60 mg靜脈滴註1次/d,共3週.觀察治療前後神經繫統癥狀和體徵變化,測量神經傳導速度(NCV)和空腹血糖,檢查膝腱和跟腱反射、血尿常規和肝腎功能等.結果 治療組總有效率為91.84％,明顯高于對照組的67.35％(χ2=52.01,P＜0.05).治療後治療組運動神經傳導速度(MNCV)、感覺神經傳導速度(SNCV)增加幅度均顯著高于對照組(t=1.987、1.972、1.972、1.972,均P＜0.05).結論 ALA聯閤GM1治療糖尿病週圍神經病變安全、療效明顯.
목적 탐토α-류신산(ALA)연합단타액산사기당신경절감지(GM1)치료당뇨병주위신경병변(DPN)적치료효과.방법 장98례2형당뇨병(T2DM)반유DPN적환자준조지정동의원칙채용수궤수자표법분위대조조화치료조,각49례.대조조급여ALA 600 mg정맥적주1차/d,치료조재대조조적기출상가용GMI 60 mg정맥적주1차/d,공3주.관찰치료전후신경계통증상화체정변화,측량신경전도속도(NCV)화공복혈당,검사슬건화근건반사、혈뇨상규화간신공능등.결과 치료조총유효솔위91.84％,명현고우대조조적67.35％(χ2=52.01,P＜0.05).치료후치료조운동신경전도속도(MNCV)、감각신경전도속도(SNCV)증가폭도균현저고우대조조(t=1.987、1.972、1.972、1.972,균P＜0.05).결론 ALA연합GM1치료당뇨병주위신경병변안전、료효명현.
Objective To explore the therapeutic effect of alpha-lipoic acid(ALA) combined with monosialotetrahexosylganglioside(GM1) in the treatment of diabetic peripheral neuropathy (DPN).Methods According to random number table,98 type 2 diabetic patients with DPN were divided into the control group and treatment group according to the principle of informed consent,each group 49 cases.The control group was treated with ALA 600mg/d by intravenous drip infusion once a day for 3 weeks.The treatment group was treated with ALA 600mg/d and GM1 60mg by intravenous drip infusion once a day for 3 weeks.The changes of nerve system symptoms and signs were observed before and after treatment,measurement of nerve conduction velocity (NCV) and fasting blood glucose,examination of knee tendon and Achilles tendon reflex,blood and urine routine and hepatic and renal function.Results The total effective rate of treatment group was 91.84％,which was higher than that of the control group (67.35 ％) (χ2 =52.01,P ＜ 0.05).After the treatment,the motor nerve conduction velocity (MNCV),sensory nerve conduction velocity(SNCV) of the treatment group increased significantly higher than those of the control group(t =1.987,1.972,1.972,1.972,all P＜0.05).Conclusion ALA combined with GM1 in the treatment of DPN is safe and effective.
